VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | Should we treat high-risk DLBCL differently?

Ulrich Jäger, MD, of Medical University of Vienna, Vienna, Austria, discusses the critical issue of whether we should treat high-risk diffuse large B-cell lymphoma (DLBCL) differently. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter